| Entry |
|
|---|
| Name |
Ciclesonide (JAN/USAN/INN);
Alvesco (TN);
Omnaris (TN);
Zetonna (TN)
|
|---|
| Product |
|
|---|
| Formula |
C32H44O7
|
|---|
| Exact mass |
540.3087
|
|---|
| Mol weight |
540.6876
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Anti-inflammatory
DG01955 Corticosteroid
DG02068 Glucocorticoid
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 2290 |
|
|---|
| Efficacy |
Antiasthmatic, Anti-inflammatory, Glucocorticoid receptor agonist |
|---|
| Disease |
|
|---|
| Comment |
Glucocorticoid, acetal derivative
Treatment of asthma as prophylactic therapy in adults and adolescents
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R01 NASAL PREPARATIONS
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01AD Corticosteroids
R01AD13 Ciclesonide
D01703 Ciclesonide (JAN/USAN/INN) <JP/US>
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03BA Glucocorticoids
R03BA08 Ciclesonide
D01703 Ciclesonide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Anti-inflammatories, Inhaled Corticosteroids
Ciclesonide
D01703 Ciclesonide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
22 Respiratory organ agents
229 Miscellaneous
2290 Miscellaneous
D01703 Ciclesonide (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Estrogen like receptors
3-Ketosteroid receptor
NR3C1 (GR)
D01703 Ciclesonide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01703
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01703
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01703
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 39
1 C2x C 14.0700 -23.5900
2 C5x C 14.0700 -24.9900
3 C2x C 15.2600 -25.6900
4 C2y C 16.5200 -24.9900
5 C1z C 16.5200 -23.5900
6 C2x C 15.2600 -22.8900
7 C1x C 17.7100 -25.6900
8 C1x C 18.9000 -24.9900
9 C1y C 18.9000 -23.5900
10 C1y C 17.7100 -22.8900
11 C1y C 20.1600 -22.8900
12 C1z C 20.1600 -21.4900
13 C1x C 18.9000 -20.7900
14 C1y C 17.7100 -21.4900
15 C1x C 22.5400 -22.8900
16 C1y C 22.5400 -21.4900
17 C1z C 21.3500 -20.7900
18 O5x O 12.8800 -25.6900
19 C1a C 16.5200 -22.1900
20 C1a C 20.1600 -20.0900
21 O1a O 16.5200 -20.7900
22 C5a C 21.3500 -19.3900
23 O5a O 22.5400 -18.6900
24 C1b C 20.1600 -18.6900
25 O7a O 20.1600 -17.2900
26 C7a C 18.9700 -16.5900
27 C1c C 17.7800 -17.2900
28 O6a O 18.9700 -15.1900
29 C1a C 16.5900 -16.5900
30 C1a C 17.7800 -18.6900
31 O2x O 22.5400 -20.0900
32 O2x O 23.9400 -21.1400
33 C1y C 23.9400 -20.0900
34 C1x C 25.1300 -17.9900
35 C1y C 25.1300 -19.3900
36 C1x C 26.3200 -20.0900
37 C1x C 27.5800 -19.3900
38 C1x C 27.5800 -17.9900
39 C1x C 26.3200 -17.2900
BOND 44
1 1 2 1
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 5 10 1
12 9 11 1
13 11 12 1
14 12 13 1
15 13 14 1
16 10 14 1
17 11 15 1
18 15 16 1
19 16 17 1
20 12 17 1
21 2 18 2
22 5 19 1 #Up
23 12 20 1 #Up
24 14 21 1 #Up
25 17 22 1 #Up
26 22 23 2
27 22 24 1
28 24 25 1
29 25 26 1
30 26 27 1
31 26 28 2
32 27 29 1
33 27 30 1
34 17 31 1
35 16 32 1
36 31 33 1
37 32 33 1
38 34 35 1
39 35 36 1
40 36 37 1
41 37 38 1
42 38 39 1
43 34 39 1
44 33 35 1 #Down
|
|---|
